Jennerex Research Collaboration with Ottawa Hospital Research Institute Receives $10 M Grant from OICR
News Jun 12, 2009
Jennerex, Inc. has announced that a $10 million grant from the Ontario Institute for Cancer Research (OICR) has been received by the Centre for Cancer Therapeutics at Ottawa Hospital Research Institute (OHRI).
A large portion of this grant will fund research and development in the lab of Dr. John Bell, Jennerex's chief collaborator for the discovery and development of oncolytic viral therapeutics for cancer patients.
Funding will support the translation of discoveries into medical products with the potential to prolong the lives of cancer patients. The grant, which provides $10 million (CAD) over four years, will fund the research and development of novel therapeutics including the development of Jennerex's oncolytic viral therapy products. Jennerex products have shown tumor destruction and safety in Phase 1 and 2 clinical trials.
"We are very pleased that Dr. Bell and Jennerex's oncolytic virus technologies have been given this vote of confidence by the Ontario Institute for Cancer Research. This funding will bolster the translation of Dr. Bell's promising research into important cancer therapeutics," stated David H. Kirn, M.D., president and chief executive officer of Jennerex. "We believe that there is significant potential in Ontario for medical innovation and development, and we value our partnerships in Ontario a great deal."
"This collaboration has been a great example of academia and industry working together to translate biological research into cutting edge therapies quickly and effectively," said Dr. John Bell, Senior Scientist at the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa.
Jennerex is conducting Phase 2 clinical trials for several types of cancer in Ontario, Canada. In addition, the company has a strong and collaborative relationship with world class investigators at OHRI. Jennerex oncolytic virus products are being manufactured in the "Mulcahy Manufacturing Unit" at OHRI, Ontario's first GMP facility dedicated to oncolytic virus production. Some of these development costs will be covered by the OICR grant. Some of the translational research funding will help support R&D, including human trials on Jennerex clinical candidates JX-594 and JX-929.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019